CHILDRENS CANCER GROUP

儿童癌症组

• 批准号: 2719557
• 负责人: PHILIP P BREITFELD
• 金额: $ 22.58万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 1994
• 资助国家: 美国
• 起止时间: 1994-03-11 至 2002-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2719557
• 关键词: acute lymphocytic leukemia; acute myelogenous leukemia; antineoplastics; bone marrow transplantation; bone neoplasms; brain neoplasms; clinical research; clinical trials; combination cancer therapy; combination chemotherapy; cooperative study; cytogenetics; data management; human subject; human therapy evaluation; liver neoplasms; lymphoma; molecular oncology; neoplasm /cancer chemotherapy; neoplasm /cancer diagnosis; neoplasm /cancer epidemiology; neoplasm /cancer immunotherapy; neoplasm /cancer pharmacology; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; neuroblastoma; oncology nursing; pediatric neoplasm /cancer; statistics /biometry; tissue resource /registry

This is a proposal for the continued support of Indiana University's participation in the Children's Cancer Group (CCG) activities. Indiana University has been a funded member of CCG since 1971. The Indiana University childhood cancer program has recruited substantial numbers of patients into CCG studies and consistently has ranked in the top 10 of 35 of CCG institutions. This should continue as this program remains the major referral center for the State of Indiana and is committed to CCG participation. This application supports the efforts of 41 Indiana University investigators and support staff. Additional strengths of the Indiana program which serve the interests of CCG include basic and translational research. Funding from the NIH/NCI for childhood cancer research at the Indiana University program was 2.9M dollars for 1995-1996. Areas of expertise are in basic hematopoiesis, DNA repair and gene therapy. Translational efforts include the use of peripheral blood progenitor cells for hematopoietic support, and gene therapy and DNA repair proteins to off-set hematopoietic toxicity of chemotherapy. These efforts have already lead to Drs. Jakacki and Kreissman acting as study chairs for novel translational studies within the CCG targetted for brain tumors and neuroblastoma. Similar efforts in gene therapy at the institutional level may be ready for limited institutional CCG trials in 3-5 years. The Indiana program can be expected to feed the CCG with pilot data for these novel translational studies. This should greatly aid efforts directed toward the development of scientifically-based, hypothesis-driven research aims within the CCG. Indiana investigators chair 6 scientific committees, 7 serve on disease strategy groups, and have chaired 11 studies during the 1992-1997 period. Finally, multidisciplinary expertise is represented in the areas of cytogenetics (Heerema), local tumor control (Rescorla), and tumor imaging (Cohen). The Indiana group remains dedicated to the understanding and development of better treatment for children with cancer through its participation in the CCG.

这是一份关于继续支持印第安纳大学参与儿童癌症小组 (CCG) 活动的提案。 印第安纳大学自 1971 年以来一直是 CCG 的资助成员。印第安纳大学儿童癌症项目已招募了大量患者参与 CCG 研究，并始终位列 35 个 CCG 机构中的前 10 名。这种情况应该继续下去，因为该计划仍然是印第安纳州的主要转诊中心，并致力于 CCG 的参与。 该应用程序支持 41 名印第安纳大学研究人员和支持人员的努力。印第安纳项目服务于 CCG 利益的其他优势包括基础研究和转化研究。 1995-1996 年，NIH/NCI 为印第安纳大学儿童癌症研究项目提供了 290 万美元的资助。 专业领域包括基础造血、DNA 修复和基因治疗。 转化努力包括使用外周血祖细胞支持造血，以及基因治疗和 DNA 修复蛋白来抵消化疗的造血毒性。 这些努力已经导致博士。 Jakacki 和 Kreissman 担任 CCG 内针对脑肿瘤和神经母细胞瘤的新型转化研究的研究主席。 机构层面在基因治疗方面的类似努力可能会在 3-5 年内为有限的机构 CCG 试验做好准备。 印第安纳州计划有望为 CCG 提供这些新颖转化研究的试点数据。这应该会极大地帮助 CCG 内致力于发展以科学为基础、假设驱动的研究目标。印第安纳州的研究人员在 1992 年至 1997 年间主持了 6 个科学委员会，其中 7 个在疾病战略小组中任职，并主持了 11 项研究。 最后，多学科专业知识体现在细胞遗传学 (Heerema)、局部肿瘤控制 (Rescorla) 和肿瘤成像 (Cohen) 领域。 印第安纳小组通过参与 CCG，始终致力于了解和开发更好的儿童癌症治疗方法。